A Study to Evaluate Minimal Residual Disease in Chronic Lymphocytic Leukemia


About this study

The purpose of this study is to compare whether minimal residual disease (MRD) flow cytometric assay is not affected by different anticoagulants.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18+ Years Old.
  • Diagnosis of Chronic Lymphocytic Leukemia (B-CLL).

Exclusion Criteria:

  • Pregnant.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sameer Parikh, M.B.B.S.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer